AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Rajiv Shah and Tom Bumol Join PanTheryx Board of Directors as Biotech Expands Pipeline Candidates with Substantial R&D Investment

April 2, 2019

BOULDER, Colo.--(BUSINESS WIRE)--Apr 2, 2019--PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today the appointment of Dr. Rajiv Shah, MD, president of the Rockefeller Foundation, and Dr. Tom Bumol, PhD, executive director of the Allen Institute for Immunology, to its board of directors.

The addition of these two new members caps a pivotal year for PanTheryx, as its products gained traction in commercial markets and R&D activities continued to advance the company’s medical foods and biologics pipeline. “2018 was an excellent year — our flagship product, DiaResQ®, is helping children and adults worldwide with distribution agreements covering over 50 countries, along with a U.S. retail distribution footprint of over 25,000 stores,” said Mark Braman, CEO of PanTheryx. “It’s an exciting time because we’re only in the beginning stages of realizing the full potential of our patented technology platform. With the successes we’ve seen in our pre-clinical models, we’re significantly increasing our R&D investment to advance our pipeline.” As new members to the board of directors, Dr. Shah and Dr. Bumol will help guide the company’s efforts in the development of product candidates, including those with the potential to impact public health globally.

With immunology being a core component of PanTheryx’s development platform, Dr. Bumol’s expertise will help PanTheryx bring novel innovations to market, with distinct mechanisms of action that target the underlying etiology of challenging disease states. “I’m joining PanTheryx at an exciting time in its evolution,” said Dr. Bumol. “I look forward to helping the company further apply its technology within the nexus of the most promising frontiers in medicine: immunology, gut health, and the human microbiome.”

Before joining the Allen Institute, Dr. Bumol was the senior vice-president of the Biotechnology and Immunology Research component at Lilly Research Laboratories. He was also the site head of Lilly’s Biotechnology Center of San Diego, which included the former Applied Molecular Evolution subsidiary of Lilly Research Laboratories. Dr. Bumol has over 50 publications and reviews, 8 issued U.S. patents, and his team and collaborators have nominated over 100 molecules into clinical development.

With multiple candidates poised to launch out of the R&D pipeline, Dr. Shah has joined as vice-chair of the PanTheryx board of directors and will help the company further its mission of providing education, prevention, and care to the most at-risk populations in the world. “I am excited about PanTheryx’s commitment to harnessing the power of science, innovation and novel technologies to improve the lives of millions of children and families around the world, particularly those with the greatest needs.”

Dr. Shah brings over two decades of experience in business, government, and philanthropy to his board director position. Before joining the Rockefeller Foundation, Dr. Shah worked as the USAID administrator, reshaping the agency’s operations to provide greater assistance to pressing development challenges around the globe. In addition to pioneering new public-private partnerships and scientific innovation, he also led the U.S. government’s humanitarian response to crises around the world, including the Haiti earthquake, Typhoon Haiyan and the Ebola epidemic in Western Africa. Prior to that, he spent eight years at the Bill and Melinda Gates Foundation where he led efforts in global health, agriculture, and financial services.

About PanTheryx

PanTheryx is a biotechnology company committed to realizing the potential of novel interventions to address a wide range of serious GI microbiome related health conditions. The company is also the premier supplier of bovine colostrum, and leverages its vertical integration to develop and commercialize first-in-class therapeutics, with products developed from its patented technology platform spanning the range of nutritional interventions to biologics. Founded in 2007, PanTheryx is headquartered in Boulder, Colorado and has production facilities in Phoenix, AZ and Ripon, CA.

For more information, please visit www.PanTheryx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190402005851/en/

CONTACT: PanTheryx

Jess Teilborg - Vice President, Marketing

(720) 417-7325

Jessica.Teilborg@pantheryx.com

KEYWORD: UNITED STATES NORTH AMERICA COLORADO

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE

SOURCE: PanTheryx

Copyright Business Wire 2019.

PUB: 04/02/2019 11:51 AM/DISC: 04/02/2019 11:51 AM

http://www.businesswire.com/news/home/20190402005851/en